G1 Therapeutics, Inc.
NASDAQ: GTHX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John E. Bailey Jr.
- Employees
- 100
- Headquarters
- Research Triangle Park, United States
- IPO year
- 2017
- Market cap
- $377.7M
- Website
- https://www.g1therapeutics.com
Loading GTHX…
Loading profile data…Frequently asked questions about GTHX
What does G1 Therapeutics, Inc. (GTHX) do?
G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers. Their flagship commercial offering, COSELA, is designed to reduce chemotherapy-induced bone marrow suppression in adult patients with extensive-s...
Where does GTHX trade?
G1 Therapeutics, Inc. (GTHX) trades on the NASDAQ Global Select.
What sector is GTHX in?
G1 Therapeutics, Inc. (GTHX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of G1 Therapeutics, Inc.?
John E. Bailey Jr. is the chief executive officer of G1 Therapeutics, Inc. (GTHX).
Where is G1 Therapeutics, Inc. headquartered?
G1 Therapeutics, Inc. is headquartered in United States.
Does GTHX pay a dividend?
G1 Therapeutics, Inc. (GTHX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GTHX go public?
G1 Therapeutics, Inc. (GTHX) completed its initial public offering in 2017.